Titanium Media App reported on July 15 that the sequential immunization clinical study of the new coronavirus inactivated vaccine developed by Sinopharm China Bio-Wuhan Biological Products Research Institute (hereinafter referred to as the Austrian strain) was officially launched in Xiangyang, Hubei. The volunteers were vaccinated with the Austrian strain of the new crown inactivated vaccine after going through relevant testing, informed consent, basic physical examination, blood sampling and other links. This clinical study adopts a randomized, double-blind, and controlled study design. People aged 18 and above who have been vaccinated with the new crown virus inactivated vaccine are vaccinated at different intervals and in different dose sequences to evaluate the efficacy of the new crown virus inactivated vaccine of Omicron strain. Safety and Immunogenicity.
media coverage
Titanium Media 36Kr
Related events
- The clinical trial of the new crown inactivated vaccine produced in Wuhan started2022-07-15
- Sinopharm Group and Argentina reached a cooperation in phase III clinical trial of new crown inactivated vaccine2020-08-20
This article is reprinted from: https://readhub.cn/topic/8hFJFNybPbD
This site is for inclusion only, and the copyright belongs to the original author.